Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | belantamab mafodotin-blmf |
| Synonyms | |
| Therapy Description |
Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate comprising an antibody targeting BCMA linked to monomethyl auristatin F, which delivers the anti-microtubule agent to BCMA-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 30442502, PMID: 24569262). Blenrep (belantamab mafodotin-blmf) is FDA approved for use in patients with relapse or refractory multiple myeloma who have received 4 or more prior therapies (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| belantamab mafodotin-blmf | Blenrep | anti-BCMA ADC GSK2857916|J6M0-mcMMAF|GSK2857916 | TNFRSF17 Antibody 18 | Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate comprising an antibody targeting BCMA linked to monomethyl auristatin F, which delivers the anti-microtubule agent to BCMA-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 30442502, PMID: 24569262). Blenrep (belantamab mafodotin-blmf) is FDA approved for use in patients with relapse or refractory multiple myeloma who have received 4 or more prior therapies (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05117008 | Phase II | belantamab mafodotin-blmf | Maintenance Belantamab Mafodotin (Blenrep) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma (EMBRACE) | Recruiting | USA | 0 |
| NCT05091372 | Phase II | belantamab mafodotin-blmf Lenalidomide | Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | Recruiting | USA | 0 |
| NCT04676360 | Phase II | belantamab mafodotin-blmf | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma | Recruiting | USA | 0 |
| NCT04398680 | Phase I | belantamab mafodotin-blmf | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (DREAMM 13) | Recruiting | USA | 2 |
| NCT05064358 | Phase II | belantamab mafodotin-blmf | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM 14) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 11 |
| NCT05065047 | Phase I | belantamab mafodotin-blmf | Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma | Recruiting | USA | 0 |
| NCT03525678 | Phase II | belantamab mafodotin-blmf | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 0 |
| NCT05874193 | Phase II | belantamab mafodotin-blmf | A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed Refractory Myeloma (COSTA) | Not yet recruiting | USA | 0 |
| NCT05055063 | Phase I | belantamab mafodotin-blmf | A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma | Recruiting | USA | 0 |
| NCT04162210 | Phase III | Dexamethasone + Pomalidomide belantamab mafodotin-blmf | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 9 |
| NCT04398745 | Phase I | belantamab mafodotin-blmf | A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function (DREAMM12) | Recruiting | USA | 3 |
| NCT05461209 | Phase III | belantamab mafodotin-blmf Talquetamab-tgvs | A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma (MonumenTAL-5) | Withdrawn | USA | 1 |
| NCT04680468 | Phase II | belantamab mafodotin-blmf | Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma | Recruiting | USA | 0 |
| NCT05714839 | Phase I | Belantamab Belantamab + belantamab mafodotin-blmf + Dexamethasone + Lenalidomide belantamab mafodotin-blmf | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20) | Recruiting | GBR | AUS | 8 |
| NCT04126200 | Phase II | belantamab mafodotin-blmf + Isatuximab belantamab mafodotin-blmf + Dostarlimab-gxly belantamab mafodotin-blmf + GSK3359609 belantamab mafodotin-blmf + Nirogacestat belantamab mafodotin-blmf belantamab mafodotin-blmf + GSK3174998 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5) | Recruiting | USA | NLD | FRA | ESP | DEU | CAN | AUS | 10 |
| NCT05847569 | Phase II | belantamab mafodotin-blmf | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for the Treatment of Triple-Class Recurrent and/or Refractory Multiple Myeloma | Recruiting | USA | 0 |
CKB BOOST